BTIG analyst Kaveri Pohlman maintained a Hold rating on Mersana Therapeutics (MRSN – Research Report) yesterday. The company’s shares closed last Friday at $2.32.
Pohlman covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Genmab, and Ambrx Biopharma. According to TipRanks, Pohlman has an average return of -11.6% and a 32.50% success rate on recommended stocks.
Mersana Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.33.
See the top stocks recommended by analysts >>
Based on Mersana Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $7.7 million and a GAAP net loss of $41.7 million. In comparison, last year the company earned a revenue of $5.57 million and had a GAAP net loss of $59.8 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mersana Therapeutics (MRSN) Company Description:
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Read More on MRSN:
